AJ Lanigan: Indeed. In Fact, pharma companies are making massive income with therapies like Keytruda and Opdivo that deal with PD-1 and PD-L1. Right here’s the super awesome aspect: think about checkpoints as targeted visitors alerts. You don’t want an immune process that’s operating wild similar to a freight train waiting for link from Social Bookmarking